The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …

The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome,
but 5–10% of cases will develop metastatic disease. Around 60–70% of this subset, hence …

Theranostics refers to the pairing of diagnostic biomarkers with therapeutic agents that share
a specific target in diseased cells or tissues. Nuclear medicine, particularly with regard to …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Hyperthyroidism caused by Graves' disease (GD) is a relatively rare disease in children.
Treatment options are the same as in adults-anti-thyroid drugs (ATD), radio-active iodine …

Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has
increased over the last few decades. It derives from follicular thyroid cells. Generally …

Introduction Scintigraphic evaluation of the thyroid gland enables determination of the iodine-
123 iodide or the 99m Tc-pertechnetate uptake and distribution and remains the most …

This review traces the development of targeted radionuclide therapy (TRT)(the Magic Bullet)
from the discovery of radioactivity in nature and the subsequent discovery of artificial …

A search in PubMed revealed that 72 radionuclides have been considered for molecular or
functional targeted radionuclide therapy. As radionuclide therapies increase in number and …

This document provides the new EANM guideline on radioiodine therapy of benign thyroid
disease. Its aim is to guide nuclear medicine physicians, endocrinologists, and practitioners …